Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: Its use with CpG adjuvant and potential mechanisms

Journal of Infectious Diseases

Volumn 192, Issue 12, 2005, Pages 2074-2080

  Opal, Steven M ^a,d   Palardy, John E ^a   Chen, Wilbur H ^b   Parejo, Nicolas A ^a   Bhattacharjee, Apurba K ^c   Cross, Alan S ^b  

^a BROWN UNIVERSITY   (United States)

^b University of Maryland School of Medicine Center for Vaccine Development   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ESCHERICHIA COLI ENDOTOXIN; ESCHERICHIA COLI ENDOTOXIN VACCINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; ESCHERICHIA COLI VACCINE; GLYCOLIPID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; OLIGODEOXYNUCLEOTIDE; OUTER MEMBRANE PROTEIN; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CPG ISLAND; DETOXIFICATION; DRUG EFFICACY; IMMUNIZATION; INFECTION CONTROL; LETHALITY; MOUSE; NEUTROPENIA; NONHUMAN; POLYMICROBIAL SEPSIS; PRIORITY JOURNAL; SEPSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; DISEASE MODELS, ANIMAL; ENDOTOXINS; ESCHERICHIA COLI; GLYCOLIPIDS; GRAM-NEGATIVE BACTERIAL INFECTIONS; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; LIVER; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS; OLIGODEOXYRIBONUCLEOTIDES; SEPSIS; SPLEEN; SURVIVAL ANALYSIS; VACCINATION; VACCINES;

EID: 28844475232     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/498167     Document Type: Article

References (22)

1. Cross AS, Opal SM, Palardy JE, et al. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 2003; 21:4576-88.
2. Bhattacharjee AK, Opal SM, Taylor R, et al. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteremia. J Infect Dis 1996; 173:1157-63.
3. Bhattacharjee AK, Opal SM, Palardy JE, et al. Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis. J Infect Dis 1994; 170:622-9.
4. Cross AS, Opal SM, Warren SH, et al. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. J Infect Dis 2001; 183:1079-86.
5. McCluskie MJ, Weeratna RD, Davis HL. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine 2001; 19: 2657-60.
6. Wild JS, Sur S. CpG oligonucleotide modulation of allergic inflammation. Allergy 2001; 56:365-76.
7. Rothenfusser S, Tuma E, Wagner M, Endres S, Hartmann G. Recent advances in immunostimulatory CpG oligonucleotides. Curr Opin Mol Ther 2003; 5:98-106.
8. Halperin S, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003; 21:2461-7.
9. Opal SM, Sypek JP, Keith JC Jr, Schaub RG, Palardy JE, Parejo NA. Evaluation of the safety of recombinant P-selectin glycoprotein ligand immunoglobulin G fusion peptide in experimental models of localized and systemic infection. Shock 2001; 15:285-90.
10. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol 2000; 165: 4537-43.
11. Cross AS, Opal SM, Cook P, Drabick J, Bhattacharjee A. Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis. Vaccine 2004; 22:812-7.
12. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via specific CpG motif recognition. Proc Natl Acad Sci USA 2001; 98:9237-42.
13. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-4.
14. Cooper CL, Davis HL, Angel JB, et al. CpG 7909 is safe and highly effective as an adjuvant to HBV vaccine in HIV seropositive adults. AIDS (in press).
15. Cooper CL, Davis HL, Morris ML, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine, Vaccine 2004; 22:3136-43.
16. von Hunolstein C, Teloni R, Mariotti S, Recchia S, Orefici G, Nisini R. Synthetic oligodeoxynucleotide containing CpG motif induces an anti-polysaccharide type 1-like immune response after immunization of mice with Haemophilus influenzae type b conjugate. Int Immunol 2000; 12:295-303.
17. Chu RS, McCool T, Greenspan NS, Schreiber JR, Harding CV. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect Immun 2000; 68:1450-6.
18. Joseph A, Louria-Hayon I, Plis-Finarov A, et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 2002; 20:3342-54.
19. Malanchere-Bres E, Payette PJ, Mancini M, Tiollais P, Davis HL, Michel ML. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. J Virol 2001; 75:6482-91.
20. Klinman DM. CpG DNA as a vaccine adjuvant. Exp Rev Vaccines 2003; 2:305-15.
21. Gao JJ, Xue Q, Papasian CJ, Morrison DC. Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-α through a post-transcriptional mechanism. J Immunol 2001; 166:6855-60.
22. + T cell help. J Immunol 2004; 172:532-9.